Dimensional Fund Advisors LP Purchases 110,364 Shares of Enfusion, Inc. (NYSE:ENFN)

Dimensional Fund Advisors LP raised its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 16.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 798,870 shares of the company’s stock after purchasing an additional 110,364 shares during the period. Dimensional Fund Advisors LP’s holdings in Enfusion were worth $8,229,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. New York State Common Retirement Fund raised its stake in shares of Enfusion by 23.8% during the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after buying an additional 370,498 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Enfusion by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company’s stock valued at $10,823,000 after purchasing an additional 21,183 shares during the period. Wellington Management Group LLP boosted its position in shares of Enfusion by 6.1% in the 4th quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company’s stock worth $10,671,000 after purchasing an additional 59,700 shares during the last quarter. Impax Asset Management Group plc grew its stake in shares of Enfusion by 31.5% during the fourth quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock worth $9,167,000 after purchasing an additional 213,052 shares during the period. Finally, EVR Research LP bought a new stake in Enfusion in the fourth quarter valued at about $4,120,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Bronwen Bastone sold 3,126 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $35,573.88. Following the sale, the insider now directly owns 221,875 shares of the company’s stock, valued at approximately $2,524,937.50. The trade was a 1.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Neal Pawar sold 2,769 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the transaction, the chief operating officer now owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,223 shares of company stock worth $754,778 in the last 90 days. Corporate insiders own 36.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, William Blair restated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th.

Enfusion Stock Performance

Shares of NYSE:ENFN opened at $10.85 on Friday. The company has a 50 day moving average price of $10.95 and a two-hundred day moving average price of $10.62. The company has a market capitalization of $1.40 billion, a PE ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, sell-side analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.